Literature DB >> 6465423

Clinical evaluation of a new rapid heparin assay using the dye azure A.

S R Gundry, M D Klein, R A Drongowski, M M Kirsh.   

Abstract

At the present time, heparin assays are based on biologic measures of activity. They are time-consuming, difficult to reproduce, and require special devices. We have developed a colorimetric assay for chemical heparin in plasma based on the metachromasia of azure A in the presence of heparin. One milliliter of plasma is added to 1 ml of 0.08 percent azure A, vortex mixed, and read at 620 nm in a spectrophotometer. To evaluate the clinical utility of this assay, we compared it to two biologic assays of heparin effect, activated PTT and activated clotting time, and to heparin levels determined by protamine titration in 113 samples from 28 patients undergoing cardiopulmonary bypass. The activated PTT in 94 of 113 samples was greater than 600 seconds, making this test not useful due to the time required and the lack of an end point. The activated clotting time of 80 samples was less than 600 seconds. The azure A measurement of heparin concentration correlated well in this group (correlation coefficient of 0.88, p less than or equal to 0.0001). Protamine titration determinations also had excellent correlation with azure A measurements in the 111 samples tested (correlation coefficient of 0.85, p less than or equal to 0.0001). The azure A assay correlates well with the standard measures of both heparin activity and heparin concentration. It is more rapid, simple, and less expensive than either of these, and it does not depend on a bioassay of coagulation as an end point. Chemical heparin measurements with azure A may be more useful clinically than the biologic assays in determining the reversal dose of protamine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6465423     DOI: 10.1016/0002-9610(84)90219-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  6 in total

1.  Dendrigraft of Poly-l-lysine as a Promising Candidate To Reverse Heparin-based Anticoagulants in Clinical Settings.

Authors:  Benjamin Ourri; Jean-Patrick Francoia; Gerald Monard; Jean-Christophe Gris; Julien Leclaire; Laurent Vial
Journal:  ACS Med Chem Lett       Date:  2019-05-08       Impact factor: 4.345

2.  Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin.

Authors:  Tianzhi Yang; Alamdar Hussain; Shuhua Bai; Ikramy A Khalil; Hideyoshi Harashima; Fakhrul Ahsan
Journal:  J Control Release       Date:  2006-08-30       Impact factor: 9.776

3.  Complexation of a poly-L-arginine with low molecular weight heparin enhances pulmonary absorption of the drug.

Authors:  Amit Rawat; Tianzhi Yang; Alamdar Hussain; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2007-10-23       Impact factor: 4.200

4.  Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury.

Authors:  E R Edelman; D H Adams; M J Karnovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

5.  Chitosan/Alginate Nanoparticles for the Enhanced Oral Antithrombotic Activity of Clam Heparinoid from the Clam Coelomactra antiquata.

Authors:  Guan-Lan Chen; Hong-Ying Cai; Jian-Ping Chen; Rui Li; Sai-Yi Zhong; Xue-Jing Jia; Xiao-Fei Liu; Bing-Bing Song
Journal:  Mar Drugs       Date:  2022-02-12       Impact factor: 5.118

6.  Antithrombotic Activity of Heparinoid G2 and Its Derivatives from the Clam Coelomactra antiquata.

Authors:  Guanlan Chen; Rui Zeng; Xin Wang; Hongying Cai; Jiajia Chen; Yingxiong Zhong; Saiyi Zhong; Xuejing Jia
Journal:  Mar Drugs       Date:  2022-01-05       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.